drugset / Trial / NCT03321318

AK-R215 Pharmacokinetic Study Phase I

NCT03321318

Phase 1 Unknown 52 enrolled Alvogen Korea
RandomizedCrossoverOpen-labelTreatment

Summary

An open label, randomized, 2-sequence, 2-period, single-dose cross-over study to evaluate the pharmacokinetics characteristics of AK-R215

Timeline

Start
2017-07-13
Primary completion
2017-09-18
Completion
2018-01-12

Drugs

EvaluationDrugModalityDoseRoute
Subject AK-R215 Unknown
Subject Bazedoxifene Other / unclassified 20 mg
Subject Cholecalciferol Other / unclassified 800 iu

Indications

No indication recorded.